JAFRAL is going to attend The Phage Futures 2019 in Washington, US. You are welcome to meet with our representative at the conference dr. Frenk Smrekar [...]

JAFRAL is proud to be a GMP manufacturing partner of a consortium/project for first clinical trial on combined electrochemotherapy with gene therapy with Interleukin-12 (IL-12) to improve/enhance local and systemic response to skin tumor treatment.

As of June 1 2018 JAFRAL is a part of Bio-Pharm Competence Center for Biotechnology and Pharmaceuticals.

On 20th September 2017, WHO launched report about antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis. Report shows a

JAFRAL is going to attend and co-sponsor at Viruses of Microbes 2018 in Wroclaw, Poland.

JAFRAL is going to attend and held presentation at Phage Therapy & Antibiotic Resistance 2018 in Florence, Italy. You are welcome to meet with our representative at the conference dr. Frenk Smrekar